



## Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results

**2008 Full-Year Sales of \$63.7 Billion increased 4.3%; Full-Year EPS was \$4.57**

**2008 Fourth-Quarter Sales of \$15.2 Billion decreased 4.9%; EPS was \$0.97**

**Excluding Special Items, 2008 Full-Year EPS was \$4.55, an increase of 9.6% and Fourth-Quarter EPS was \$0.94, an increase of 6.8%\***

NEW BRUNSWICK, N.J., Jan 20, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson today announced sales for the year 2008 of \$63.7 billion, an increase of 4.3% over 2007. Operational growth was 1.9% with currency contributing 2.4%. Domestic sales decreased 0.4%, while international sales increased 9.7%, reflecting operational growth of 4.6% and a positive currency impact of 5.1%. Worldwide sales in the fourth quarter of 2008 were \$15.2 billion, a decrease of 4.9% as compared to the fourth quarter of 2007. Operational results declined 1.0% and the negative impact of currency was 3.9%. Domestic sales decreased 6.9%, while international sales decreased 2.7%, reflecting operational growth of 5.4% and a negative currency impact of 8.1%.

Net earnings and diluted earnings per share for the year 2008 were \$12.9 billion and \$4.57. Full-year 2008 net earnings included special items related to in-process research and development charges of \$181 million with no tax benefit and an after-tax gain of \$229 million representing the net impact of litigation settlements in the fourth quarter. Full-year 2007 net earnings included special items related to an in-process research and development charge of \$807 million with no tax benefit, an after-tax charge of \$528 million for restructuring, an after-tax non-cash charge of \$441 million for the NATRECOR intangible asset write-down, and a tax gain of \$267 million associated with the restructuring of certain international subsidiaries. Excluding these special items, net earnings for 2008 were \$12.9 billion and earnings per share were \$4.55, representing increases of 6.8% and 9.6%, respectively, as compared with the same period in 2007. \*

Net earnings and diluted earnings per share for the fourth quarter of 2008 were \$2.7 billion and \$0.97, respectively. Fourth quarter 2008 net earnings included special items related to in-process research and development charges of \$141 million with no tax benefit and an after-tax gain of \$229 million representing the net impact of litigation settlements. Fourth quarter 2007 net earnings included special items related to an after-tax non-cash charge of \$441 million for the NATRECOR asset write-down and a tax gain of \$267 million associated with the restructuring of certain international subsidiaries. Excluding these special items, net earnings for the current quarter were \$2.6 billion and diluted earnings per share were \$0.94, representing increases of 3.1% and 6.8%, respectively, as compared to the same period in 2007. \*

The Company announced earnings guidance for full-year 2009 of \$4.45 to \$4.55 per share, which excludes the impact of special items. This guidance includes anticipated dilution of \$.03 to \$.05 from the acquisition of Mentor Corporation, which is expected to close in January 2009.

"I am extremely proud of Johnson & Johnson's accomplishments in 2008 and the way our people met our commitments," said William C. Weldon, Chairman and Chief Executive Officer. "We delivered solid earnings growth and made significant progress in our research pipelines while continuing to invest in the future growth of our business. I am confident that we are well positioned for continued leadership and growth in health care."

The Worldwide Consumer segment achieved annual sales in 2008 of \$16.0 billion, an increase of 10.8% over the prior year with operational growth of 8.3% and a positive impact from currency of 2.5%. Domestic sales increased 8.3%, while international sales increased 12.8% (8.3% from operations and 4.5% from currency).

Sales results reflect the strong performance of the U.S. launch of ZYRTEC, an over-the-counter allergy treatment; the skin care lines of NEUTROGENA, AVEENO and CLEAN & CLEAR; international sales of Baby Care products; and LISTERINE antiseptic mouthrinse. Also contributing to growth were sales from the recently completed acquisition of DABAO, the leading moisturizer in China.

Worldwide Pharmaceutical sales of \$24.6 billion for the full-year 2008 represented a decrease of 1.2% versus the prior year with a decline of 3.1% operationally and a positive impact from currency of 1.9%. Domestic sales decreased 4.9%, while international sales increased 5.1% (0.1% from operations and 5.0% from currency).

Sales results reflect the strong performance of VELCADE, a treatment for multiple myeloma; REMICADE, a biologic approved for the treatment of a number of immune mediated inflammatory diseases; RISPERDAL CONSTA, an antipsychotic medication; and TOPAMAX, an antiepileptic and a treatment for the prevention of migraine headaches. Sales results of RISPERDAL, an antipsychotic medication, were negatively impacted by generic competition and sales of PROCRI, a product for the treatment of anemia, were lower due to a decline in the market.

During the quarter, the Company announced that the U.S. Food and Drug Administration (FDA) approved tapentadol immediate-release tablets for the relief of moderate to severe acute pain in adults 18 years of age or older. In addition, the Company submitted two New Drug Applications to the FDA: trabectedin (known as YONDELIS outside the U.S.) when administered in combination with DOXIL for the treatment of women with relapsed ovarian cancer and carisbamate, a new investigational compound for the adjunctive treatment of partial onset seizures in patients 16 years of age and older. The FDA also granted PREZISTA, a protease inhibitor, approval for an expanded indication for once-daily dosing as part of HIV combination therapy in treatment-naïve adults and traditional approval as twice-daily for use in treatment-experienced adult patients. Outside the United States, the European Commission granted full approval of the Marketing Authorization of PREZISTA in combination with ritonavir and other antiretroviral medicinal products for the treatment of HIV-1 infection, and extended the indication to include all treatment-experienced adult patients.

Worldwide, the Medical Devices and Diagnostics segment achieved annual sales of \$23.1 billion in 2008, representing an increase over the prior year of 6.4% with operational growth of 3.5% and a positive currency impact of 2.9%. Domestic sales increased 1.0%, while international sales increased 11.3% (5.8% from operations and 5.5% from currency).

Primary contributors to the operational growth included Ethicon Endo-Surgery's minimally invasive products; Vistakon's disposable contact lenses; and DePuy's orthopaedic joint reconstruction and sports medicine businesses. This growth was partially offset by lower sales in the Cordis franchise, reflecting new competitive entries in the drug-eluting stent market.

During the quarter, the Company completed the acquisition of SurgRx, Inc., a privately held developer of the advanced bipolar tissue sealing system used in the ENSEAL family of devices, and the divestiture of Ethicon's Professional Wound Care business to One Equity Partners. In addition, the Company completed the acquisition of Omrix Biopharmaceuticals, Inc., a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products.

Also in the quarter, the Company entered into a definitive agreement to acquire Mentor Corporation, a leading supplier of medical products for the global aesthetic market.

The Company also announced 510(k) clearance from the FDA for the VITROS 5600 Integrated System, a next generation system uniquely designed to integrate clinical chemistry and immunoassay testing to increase laboratory productivity, and the VITROS 3600 Immunodiagnostic System, a new high-capacity system which combines accuracy and efficiency with a broad menu of immunoassays.

As an initial step in the creation of a wellness and prevention business platform, the Company completed two acquisitions during the quarter: HealthMedia, Inc., a privately held company that creates web-based behavior change interventions, and LGE Performance Systems, Inc., a privately held company known as Human Performance Institute, which develops science-based training programs to improve employee engagement and productivity.

#### About Johnson & Johnson

Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our 119,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

\* Net earnings and diluted earnings per share excluding special items, such as after-tax in-process research and development charges and restructuring charges, are non-GAAP financial measures and should not be considered replacements for GAAP results. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the Investor Relations section of the Company's website at [www.jnj.com](http://www.jnj.com).

Johnson & Johnson will conduct a meeting with members of the investment community to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at [www.investor.jnj.com](http://www.investor.jnj.com). A replay and podcast will be available approximately two hours after the live webcast by visiting [www.investor.jnj.com](http://www.investor.jnj.com).

Copies of the financial schedules accompanying this press release are available at [www.investor.jnj.com/historical-sales.cfm](http://www.investor.jnj.com/historical-sales.cfm). The schedules include supplementary sales data, a condensed consolidated statement of earnings, sales of key products/franchises and a pharmaceutical pipeline of selected compounds in late stage development. Additional information on Johnson & Johnson can be found on the Company's website at [www.jnj.com](http://www.jnj.com).

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections.

Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at [www.sec.gov](http://www.sec.gov), [www.jnj.com](http://www.jnj.com) or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

	(Unaudited; Dollars in Millions)		FOURTH QUARTER		
	2008	2007	Percent Change		
			Total	Operations	Currency
Sales to customers by segment of business					
Consumer					
U.S.	\$1,655	1,626	1.8%	1.8	-
International	2,200	2,184	0.7	10.6	(9.9)
	3,855	3,810	1.2	6.9	(5.7)
Pharmaceutical					
U.S.	3,430	3,944	(13.0)	(13.0)	-
International	2,255	2,453	(8.1)	0.5	(8.6)
	5,685	6,397	(11.1)	(7.8)	(3.3)
Med Devices & Diagnostics					
U.S.	2,582	2,661	(3.0)	(3.0)	-
International	3,060	3,089	(0.9)	5.6	(6.5)
	5,642	5,750	(1.9)	1.6	(3.5)
U.S.	7,667	8,231	(6.9)	(6.9)	-
International	7,515	7,726	(2.7)	5.4	(8.1)
Worldwide	\$15,182	15,957	(4.9)%	(1.0)	(3.9)

	(Unaudited; Dollars in Millions)		TWELVE MONTHS		
	2008	2007	Percent Change		
			Total	Operations	Currency
Sales to customers by segment of business					
Consumer					

U.S.	\$6,937	6,408	8.3%	8.3	-
International	9,117	8,085	12.8	8.3	4.5
-----					
	16,054	14,493	10.8	8.3	2.5
	-----	-----	----	----	----
Pharmaceutical					
U.S.	14,831	15,603	(4.9)	(4.9)	-
International	9,736	9,263	5.1	0.1	5.0
-----					
	24,567	24,866	(1.2)	(3.1)	1.9
	-----	-----	----	----	----
Med Devices & Diagnostics					
U.S.	10,541	10,433	1.0	1.0	-
International	12,585	11,303	11.3	5.8	5.5
-----					
	23,126	21,736	6.4	3.5	2.9
	-----	-----	----	----	----
U.S.	32,309	32,444	(0.4)	(0.4)	-
International	31,438	28,651	9.7	4.6	5.1
-----					
Worldwide	\$63,747	61,095	4.3%	1.9	2.4
-----					

Johnson & Johnson and Subsidiaries

-----  
Supplementary Sales Data

(Unaudited; Dollars in Millions)

FOURTH QUARTER

			Percent Change		
	2008	2007	Total	Operations	Currency
	----	----	----	-----	-----
Sales to customers by geographic area					
U.S.	\$7,667	8,231	(6.9)%	(6.9)	-
-----	-----	-----	----	----	----
Europe	3,851	4,159	(7.4)	2.7	(10.1)
Western Hemisphere excluding U.S.	1,187	1,309	(9.3)	6.0	(15.3)
Asia-Pacific, Africa	2,477	2,258	9.7	9.9	(0.2)
-----	-----	-----	----	----	----
International	7,515	7,726	(2.7)	5.4	(8.1)
-----	-----	-----	----	----	----
Worldwide	\$15,182	15,957	(4.9)%	(1.0)	(3.9)
-----	-----	-----	----	----	----

TWELVE MONTHS

	Percent Change				
	2008	2007	Total	Operations	Currency
	----	----	----	-----	-----

	----	----	-----	-----	-----
Sales to customers by geographic area					
U.S.	\$32,309	32,444	(0.4)%	(0.4)	-
-----	-----	-----	-----	-----	---
Europe	16,782	15,644	7.3	1.8	5.5
Western Hemisphere excluding U.S.	5,173	4,681	10.5	7.7	2.8
Asia-Pacific, Africa	9,483	8,326	13.9	8.4	5.5
-----	-----	-----	-----	---	---
International	31,438	28,651	9.7	4.6	5.1
-----	-----	-----	---	---	---
Worldwide	\$63,747	61,095	4.3%	1.9	2.4
-----	-----	-----	---	---	---

Johnson & Johnson and Subsidiaries

-----  
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except  
Per Share Figures)

FOURTH QUARTER

	2008		2007		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
-----	-----	-----	-----	-----	-----
Sales to customers	\$15,182	100.0	\$15,957	100.0	(4.9)
-----	-----	-----	-----	-----	-----
Cost of products sold	4,372	28.8	4,734	29.7	(7.6)
Selling, marketing and administrative expenses	5,665	37.3	5,721	35.8	(1.0)
Research expense	2,108	13.9	2,328	14.6	(9.5)
In-process research & development (IPR&D)	141	0.9	-	-	
Restructuring expense	-	-	-	-	
Interest (income) expense, net	17	0.1	(35)	(0.2)	
Other (income) expense, net	(638)	(4.2)	877	5.5	
-----	-----	-----	-----	-----	-----
Earnings before provision for taxes on income	3,517	23.2	2,332	14.6	50.8
Provision for taxes on income	803	5.3	(42)	(0.3)	NM*
-----	-----	-----	-----	-----	---
Net earnings	\$2,714	17.9	\$2,374	14.9	14.3
-----	-----	-----	-----	-----	-----
Net earnings per share (Diluted)	\$0.97		\$0.82		18.3

Average shares outstanding (Diluted)	2,801.6		2,889.2		
Effective tax rate	22.8%		(1.8)%		
-----					
Adjusted earnings before provision for taxes and net earnings					
Earnings before provision for taxes on income	\$3,279 (1)	21.6	\$3,010 (2)	18.9	8.9
Net earnings	\$2,626 (1)	17.3	\$2,548 (2)	16.0	3.1
Net earnings per share (Diluted)	\$0.94 (1)		\$0.88 (2)		6.8
Effective tax rate	19.9%		15.3%		
-----					

(1) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of IPR&D of \$141 million with no tax benefit and \$0.05 per share, respectively and the exclusion of income representing the net impact of litigation settlements of \$379 million, \$229 million, and \$0.08 per share, respectively.

(2) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of the NATRECOR(R) intangible asset write-down of \$678 million, \$441 million, and \$0.15 per share, respectively, and the exclusion of an international tax gain on restructuring of \$267 million on net earnings, and \$0.09 per share.

\*Not meaningful

#### Johnson & Johnson and Subsidiaries

#### Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	TWELVE MONTHS				
	2008		2007		
	Amount	Percent to Sales	Amount	Percent to Sales	Percent Increase (Decrease)
Sales to customers	\$63,747	100.0	\$61,095	100.0	4.3
Cost of products sold	18,511	29.1	17,751	29.1	4.3
Selling, marketing and administrative expenses	21,490	33.7	20,451	33.5	5.1
Research expense	7,577	11.9	7,680	12.6	(1.3)
In-process research					

& development					
(IPR&D)	181	0.3	807	1.3	
Restructuring expense	-	-	745	1.2	
Interest					
(income)expense, net	74	0.1	(156)	(0.3)	
Other (income)					
expense, net	(1,015)	(1.6)	534	0.9	
-----	-----	----	---	---	----
Earnings before					
provision for taxes					
on income	16,929	26.5	13,283	21.7	27.4
Provision for taxes					
on income	3,980	6.2	2,707	4.4	47.0
-----	-----	---	-----	---	----
Net earnings	\$12,949	20.3	\$10,576	17.3	22.4
-----	-----	----	-----	----	----
Net earnings per					
share (Diluted)	\$4.57		\$3.63		25.9
Average shares					
outstanding					
(Diluted)	2,835.6		2,910.7		
Effective tax rate	23.5%		20.4%		

-----  
Adjusted earnings  
before provision for  
taxes and net earnings

Earnings before					
provision for taxes					
on income	\$16,731 (1)	26.2	\$15,513 (2)	25.4	7.9
Net earnings	\$12,901 (1)	20.2	\$12,085 (2)	19.8	6.8
Net earnings per					
share (Diluted)	\$4.55 (1)		\$4.15 (2)		9.6
Effective tax rate	22.9%		22.1%		
-----	-----	----	-----	----	----

(1) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of IPR&D of \$181 million with no tax benefit and \$0.06 per share, respectively, and the exclusion of income representing the net impact of litigation settlements in the fourth quarter of \$379 million, \$229 million, and \$0.08 per share, respectively.

(2) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of IPR&D of \$807 million with no tax benefit and \$0.28 per share, respectively, the exclusion of the restructuring expense of \$745 million, \$528 million and \$0.18 per share, respectively, the exclusion of the NATRECOR(R) intangible asset write-down of \$678 million, \$441 million, and \$0.15 per share, respectively, and the exclusion of an international tax gain on restructuring of \$267 million on net earnings, and \$0.09 per share.

-----  
\$MM  
---

FOURTH QUARTER  
-----

% Change  
-----

	2008	2007	Reported	Operational (1)	Currency
	-----	-----	-----	-----	-----
PHARMACEUTICAL SEGMENT (2) (3) -----					
ACIPHEX/PARIET -----					
US	140	166	-15.7%	-15.7%	-
Intl	134	181	-26.0%	-15.5%	-10.5%
WW	274	347	-21.0%	-15.6%	-5.4%
CONCERTA -----					
US	208	222	-6.3%	-6.3%	-
Intl	72	67	7.5%	34.3%	-26.8%
WW	280	289	-3.1%	3.1%	-6.2%
DURAGESIC/FENTANYL TRANSDERMAL -----					
US	72	72	0.0%	0.0%	-
Intl	200	192	4.2%	10.4%	-6.2%
WW	272	264	3.0%	7.5%	-4.5%
LEVAQUIN/FLOXIN -----					
US	393	409	-3.9%	-3.9%	-
Intl	18	23	-21.7%	-7.7%	-14.0%
WW	411	432	-4.9%	-4.2%	-0.7%
PROCRIT/EPREX -----					
US	318	331	-3.9%	-3.9%	-
Intl	242	297	-18.5%	-8.2%	-10.3%
WW	560	628	-10.8%	-5.9%	-4.9%
RAZADYNE/REMINYL -----					
US	11	49	-77.6%	-77.6%	-
Intl	91	92	-1.1%	12.1%	-13.2%
WW	102	141	-27.7%	-19.1%	-8.6%
REMICADE -----					
US	672	661	1.7%	1.7%	-
US Exports (4)	209	246	-15.0%	-15.0%	-
Intl	5	1	400.0%	385.4%	14.6%
WW	886	908	-2.4%	-2.4%	-
RISPERDAL/RISPERIDONE -----					
US	91	570	-84.0%	-84.0%	-
Intl	194	304	-36.2%	-33.6%	-2.6%
WW	285	874	-67.4%	-66.5%	-0.9%



## RISPERDAL CONSTA

-----

US	117	108	8.3%	8.3%	-
Intl	202	187	8.0%	20.9%	-12.9%
WW	319	295	8.1%	16.3%	-8.2%

## TOPAMAX

-----

US	576	535	7.7%	7.7%	-
Intl	104	117	-11.1%	0.9%	-12.0%
WW	680	652	4.3%	6.4%	-2.1%

## VELCADE

-----

US	-	3	-100.0%	-100.0%	-
Intl	208	162	28.4%	35.9%	-7.5%
WW	208	165	26.1%	33.5%	-7.4%

## OTHER

-----

US	623	572	8.9%	8.9%	-
Intl	785	830	-5.4%	3.2%	-8.6%
WW	1,408	1,402	0.4%	5.5%	-5.1%

## TOTAL PHARMACEUTICAL

-----

US	3,430	3,944	-13.0%	-13.0%	-
Intl	2,255	2,453	-8.1%	0.5%	-8.6%
WW	5,685	6,397	-11.1%	-7.8%	-3.3%

## TWELVE MONTHS

% Change

	2008	2007	Reported	Operational (1)	Currency
	----	----	-----	-----	-----

## PHARMACEUTICAL SEGMENT (2) (3)

-----

## ACIPHEX/PARIET

-----

US	539	645	-16.4%	-16.4%	-
Intl	619	712	-13.1%	-16.6%	3.5%
WW	1,158	1,357	-14.7%	-16.6%	1.9%

## CONCERTA

-----

US	830	798	4.0%	4.0%	-
Intl	417	230	81.3%	77.4%	3.9%
WW	1,247	1,028	21.3%	20.4%	0.9%

## DURAGESIC/FENTANYL TRANSDERMAL

-----

US	271	391	-30.7%	-30.7%	-
Intl	765	773	-1.0%	-6.3%	5.3%
WW	1,036	1,164	-11.0%	-14.5%	3.5%

## LEVAQUIN/FLOXIN

-----

US	1,510	1,564	-3.5%	-3.5%	-
Intl	81	82	-1.2%	-1.0%	-0.2%
WW	1,591	1,646	-3.3%	-3.3%	0.0%
PROCRIT/EXPRES					
-----					
US	1,332	1,690	-21.2%	-21.2%	-
Intl	1,128	1,195	-5.6%	-10.5%	4.9%
WW	2,460	2,885	-14.7%	-16.7%	2.0%
RAZADYNE/REMINYL					
-----					
US	134	194	-30.9%	-30.9%	-
Intl	407	337	20.8%	15.1%	5.7%
WW	541	531	1.9%	-1.7%	3.6%
REMICADE					
-----					
US	2,810	2,534	10.9%	10.9%	-
US Exports (4)	927	792	17.0%	17.0%	-
Intl	11	1	1000.0%	976.8%	23.2%
WW	3,748	3,327	12.7%	12.7%	-
RISPERDAL/RISPERIDONE					
-----					
US	1,287	2,198	-41.4%	-41.4%	-
Intl	839	1,222	-31.3%	-35.6%	4.3%
WW	2,126	3,420	-37.8%	-39.3%	1.5%
RISPERDAL CONSTA					
-----					
US	456	422	8.1%	8.1%	-
Intl	853	706	20.8%	15.2%	5.6%
WW	1,309	1,128	16.0%	12.5%	3.5%
TOPAMAX					
-----					
US	2,250	2,006	12.2%	12.2%	-
Intl	481	447	7.6%	3.4%	4.2%
WW	2,731	2,453	11.3%	10.5%	0.8%
VELCADE					
-----					
US	4	8	-50.0%	-50.0%	-
Intl	783	526	48.9%	42.1%	6.8%
WW	787	534	47.4%	40.7%	6.7%
OTHER					
-----					
US	2,481	2,361	5.1%	5.1%	-
Intl	3,352	3,032	10.6%	4.0%	6.6%
WW	5,833	5,393	8.2%	4.5%	3.7%
TOTAL PHARMACEUTICAL					
-----					
US	14,831	15,603	-4.9%	-4.9%	-
Intl	9,736	9,263	5.1%	0.1%	5.0%
WW	24,567	24,866	-1.2%	-3.1%	1.9%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Prior year amounts have been reclassified to conform with current presentation

(4) For external purposes, reported as U.S. sales

		FOURTH QUARTER			
		-----			
		% Change			
		-----			
	2008	2007	Reported	Operational (1)	Currency
	----	----	-----	-----	-----
MEDICAL DEVICES AND DIAGNOSTICS (2) (3)					
CORDIS (4)					
-----					
US	253	394	-35.8%	-35.8%	-
Intl	469	474	-1.1%	1.3%	-2.4%
WW	722	868	-16.8%	-15.5%	-1.3%
DEPUY					
-----					
US	727	661	10.0%	10.0%	-
Intl	525	548	-4.2%	6.2%	-10.4%
WW	1,252	1,209	3.6%	8.3%	-4.7%
DIABETES CARE					
-----					
US	275	337	-18.4%	-18.4%	-
Intl	304	306	-0.7%	7.5%	-8.2%
WW	579	643	-10.0%	-6.1%	-3.9%
ETHICON ENDO-SURGERY					
-----					
US	515	481	7.1%	7.1%	-
Intl	602	583	3.3%	11.6%	-8.3%
WW	1,117	1,064	5.0%	9.0%	-4.0%
ETHICON (5)					
-----					
US	363	353	2.8%	2.8%	-
Intl	555	591	-6.1%	3.5%	-9.6%
WW	918	944	-2.8%	3.3%	-6.1%
ORTHO-CLINICAL DIAGNOSTICS (5)					
-----					
US	248	245	1.2%	1.2%	-
Intl	204	211	-3.3%	2.3%	-5.6%
WW	452	456	-0.9%	1.7%	-2.6%
VISION CARE					
-----					
US	201	190	5.8%	5.8%	-
Intl	401	376	6.6%	5.5%	1.1%
WW	602	566	6.4%	5.7%	0.7%
TOTAL MEDICAL DEVICES AND DIAGNOSTICS					
-----					
US	2,582	2,661	-3.0%	-3.0%	-
Intl	3,060	3,089	-0.9%	5.6%	-6.5%
WW	5,642	5,750	-1.9%	1.6%	-3.5%

		TWELVE MONTHS			
		-----			
		% Change			
		-----			
	2008	2007	Reported	Operational (1)	Currency
	----	----	-----	-----	-----
MEDICAL DEVICES AND DIAGNOSTICS (2) (3)					
CORDIS (4)					
-----					
US	1,235	1,588	-22.2%	-22.2%	-
Intl	1,900	1,837	3.4%	-3.1%	6.5%
WW	3,135	3,425	-8.5%	-12.0%	3.5%
DEPUY					
-----					
US	2,803	2,638	6.3%	6.3%	-
Intl	2,186	1,949	12.2%	8.3%	3.9%
WW	4,989	4,587	8.8%	7.1%	1.7%
DIABETES CARE					
-----					
US	1,265	1,260	0.4%	0.4%	-
Intl	1,270	1,113	14.1%	7.8%	6.3%
WW	2,535	2,373	6.8%	3.9%	2.9%
ETHICON ENDO-SURGERY					
-----					
US	1,901	1,792	6.1%	6.1%	-
Intl	2,385	2,042	16.8%	11.3%	5.5%
WW	4,286	3,834	11.8%	8.8%	3.0%
ETHICON (5)					
-----					
US	1,450	1,399	3.6%	3.6%	-
Intl	2,390	2,204	8.4%	4.0%	4.4%
WW	3,840	3,603	6.6%	3.9%	2.7%
ORTHO-CLINICAL DIAGNOSTICS (5)					
-----					
US	997	944	5.6%	5.6%	-
Intl	844	761	10.9%	5.0%	5.9%
WW	1,841	1,705	8.0%	5.4%	2.6%
VISION CARE					
-----					
US	890	812	9.6%	9.6%	-
Intl	1,610	1,397	15.2%	8.0%	7.2%
WW	2,500	2,209	13.2%	8.6%	4.6%
TOTAL MEDICAL DEVICES AND DIAGNOSTICS					
-----					
US	10,541	10,433	1.0%	1.0%	-
Intl	12,585	11,303	11.3%	5.8%	5.5%
WW	23,126	21,736	6.4%	3.5%	2.9%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Prior year amounts have been reclassified to conform with current presentation

(4) Includes sales of Drug-Eluting Stents for Q4 2008 of \$70, \$202 and \$272 million Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for Q4 2007 of \$189, \$225 and \$414 million Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for Dec YTD 2008 of \$503, \$852 and \$1,355 million Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for Dec YTD 2007 of \$818, \$943 and \$1,761 million Domestic, International and Worldwide respectively

(5) Prior year amounts include sales previously reported as "other"

FOURTH QUARTER

% Change

	2008	2007	Reported	Operational (1)	Currency
CONSUMER SEGMENT (2)					
SKIN CARE					
US	343	323	6.2%	6.2%	-
Intl	501	470	6.6%	15.3%	-8.7%
WW	844	793	6.4%	11.5%	-5.1%
BABY CARE					
US	109	116	-6.0%	-6.0%	-
Intl	414	421	-1.7%	5.7%	-7.4%
WW	523	537	-2.6%	3.2%	-5.8%
ORAL CARE					
US	192	189	1.6%	1.6%	-
Intl	204	190	7.4%	19.3%	-11.9%
WW	396	379	4.5%	10.5%	-6.0%
OTC/NUTRITIONALS					
US	762	728	4.7%	4.7%	-
Intl	694	687	1.0%	12.6%	-11.6%
WW	1,456	1,415	2.9%	8.5%	-5.6%
WOMEN'S HEALTH					
US	148	148	0.0%	0.0%	-
Intl	288	313	-8.0%	1.6%	-9.6%
WW	436	461	-5.4%	1.1%	-6.5%
WOUND CARE / OTHER					
US	101	122	-17.2%	-17.2%	-
Intl	99	103	-3.9%	7.0%	-10.9%

WW	200	225	-11.1%	-6.1%	-5.0%
TOTAL CONSUMER					
-----					
US	1,655	1,626	1.8%	1.8%	-
Intl	2,200	2,184	0.7%	10.6%	-9.9%
WW	3,855	3,810	1.2%	6.9%	-5.7%

TWELVE MONTHS

-----					
% Change					
-----					
	2008	2007	Reported	Operational (1)	Currency
	----	----	-----	-----	-----

CONSUMER SEGMENT (2)

-----

SKIN CARE

-----

US	1,462	1,329	10.0%	10.0%	-
Intl	1,919	1,722	11.4%	6.7%	4.7%
WW	3,381	3,051	10.8%	8.1%	2.7%

BABY CARE

-----

US	449	444	1.1%	1.1%	-
Intl	1,765	1,538	14.8%	10.1%	4.7%
WW	2,214	1,982	11.7%	8.0%	3.7%

ORAL CARE

-----

US	780	789	-1.1%	-1.1%	-
Intl	844	699	20.7%	17.1%	3.6%
WW	1,624	1,488	9.1%	7.4%	1.7%

OTC/NUTRITIONALS

-----

US	3,061	2,620	16.8%	16.8%	-
Intl	2,833	2,522	12.3%	8.2%	4.1%
WW	5,894	5,142	14.6%	12.6%	2.0%

WOMEN'S HEALTH

-----

US	618	623	-0.8%	-0.8%	-
Intl	1,293	1,183	9.3%	4.1%	5.2%
WW	1,911	1,806	5.8%	2.4%	3.4%

WOUND CARE / OTHER

-----

US	567	603	-6.0%	-6.0%	-
Intl	463	421	10.0%	4.8%	5.2%
WW	1,030	1,024	0.6%	-1.5%	2.1%

TOTAL CONSUMER

-----

US	6,937	6,408	8.3%	8.3%	-
Intl	9,117	8,085	12.8%	8.3%	4.5%
WW	16,054	14,493	10.8%	8.3%	2.5%

- (1) Operational growth excludes the effect of currency
- (2) Select areas (unaudited)

SOURCE Johnson & Johnson

<http://www.investor.jnj.com>

Copyright © 2009 PR Newswire. All rights reserved